Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up – Should You Buy?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $14.61, but opened at $15.37. Ono Pharmaceutical shares last traded at $15.37, with a volume of 7,520 shares changing hands.

Analysts Set New Price Targets

Separately, Zacks Research upgraded Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Strong Buy”.

Ono Pharmaceutical Price Performance

The company has a quick ratio of 2.56, a current ratio of 3.02 and a debt-to-equity ratio of 0.10. The firm’s fifty day moving average price is $14.33 and its 200 day moving average price is $14.78. The stock has a market cap of $7.22 billion, a PE ratio of 14.64 and a beta of 0.33.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.